Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Conrad

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Neuroimage. Clinical|February 9, 2022
White matter volume loss drives cortical reshaping after thalamic infarctsJulian Conrad, Maximilian Habs, Ria M Ruehl, et al.
Communications Medicine|July 25, 2024
Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patientsJochen H Weishaupt, Péter Körtvélyessy, Peggy Schumann, et al.
The Lancet. Neurology|February 8, 2018
Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation studyMarian Galovic, Nico Döhler, Barbara Erdélyi-Canavese, et al.
Plos Pathogens|November 16, 2022
Cryo-EM reveals the conformational epitope of human monoclonal antibody PAM1.4 broadly reacting with polymorphic malarial protein VAR2CSASai Sundar Rajan Raghavan, Robert Dagil, Mary Lopez-Perez, et al.
Nature Communications|March 5, 2025
Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosisSamir Abu-Rumeileh, Leila Scholle, Alexander Mensch, et al.
Muscle & Nerve|July 20, 2024
Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 monthsThomas Meyer, Peggy Schumann, Patrick Weydt, et al.
Brain Communications|November 3, 2025
Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcificationJanine Schwahn, Sophie Hebestreit, Olivia Kosche, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 15, 2024
Implications for driving based on the risk of seizures after ischaemic strokeKai Michael Schubert, Giulio Bicciato, Lucia Sinka, et al.
Eclinicalmedicine|February 22, 2024
Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access programMaximilian Wiesenfarth, Johannes Dorst, David Brenner, et al.
Annals of Neurology|September 10, 2021
Seizures after Ischemic Stroke: A Matched Multicenter StudyCarolina Ferreira-Atuesta, Nico Döhler, Barbara Erdélyi-Canavese, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Neuroimage. Clinical|February 9, 2022
White matter volume loss drives cortical reshaping after thalamic infarctsJulian Conrad, Maximilian Habs, Ria M Ruehl, et al.
Communications Medicine|July 25, 2024
Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patientsJochen H Weishaupt, Péter Körtvélyessy, Peggy Schumann, et al.
The Lancet. Neurology|February 8, 2018
Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation studyMarian Galovic, Nico Döhler, Barbara Erdélyi-Canavese, et al.
Plos Pathogens|November 16, 2022
Cryo-EM reveals the conformational epitope of human monoclonal antibody PAM1.4 broadly reacting with polymorphic malarial protein VAR2CSASai Sundar Rajan Raghavan, Robert Dagil, Mary Lopez-Perez, et al.
Nature Communications|March 5, 2025
Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosisSamir Abu-Rumeileh, Leila Scholle, Alexander Mensch, et al.
Muscle & Nerve|July 20, 2024
Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 monthsThomas Meyer, Peggy Schumann, Patrick Weydt, et al.
Brain Communications|November 3, 2025
Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcificationJanine Schwahn, Sophie Hebestreit, Olivia Kosche, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 15, 2024
Implications for driving based on the risk of seizures after ischaemic strokeKai Michael Schubert, Giulio Bicciato, Lucia Sinka, et al.
Eclinicalmedicine|February 22, 2024
Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access programMaximilian Wiesenfarth, Johannes Dorst, David Brenner, et al.
Annals of Neurology|September 10, 2021
Seizures after Ischemic Stroke: A Matched Multicenter StudyCarolina Ferreira-Atuesta, Nico Döhler, Barbara Erdélyi-Canavese, et al.
Pageof 5